Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
RESEARCH TOOLSreports
Holding CMMB?
Track your performance easily
CMMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $2.55
Previous Close$1.77
Volume42.30K
Average Volume (3M)147.80K
Market Cap
$33.55M
Enterprise Value$13.98M
Total Cash (Recent Filing)$19.78M
Total Debt (Recent Filing)$392.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 06, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding14,204,735
10 Day Avg. Volume95,003
30 Day Avg. Volume147,798
Standard Deviation0.25
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$8.00Price Target Upside349.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Chemomab Therapeutics News
PremiumCompany Announcements
Chemomab Therapeutics Aligns Leadership Incentives with Shareholders
PremiumCompany Announcements
Chemomab’s Positive Trial Results Boost Investor Confidence
PremiumPre-Earnings
Is CMMB a Buy, Before Earnings?
PremiumCompany Announcements
Chemomab Therapeutics Announces Shareholder Meeting
PremiumCompany Announcements
Chemomab Therapeutics Reports Mid-Year FinancialsOwnership Overview
―
Insiders
27.93% Other Institutional Investors
72.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $0.42 and its highest was $2.55 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Currently, no data Available
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 85 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.047.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 14,359,190 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Among the largest hedge funds holding Chemomab Therapeutics’s share is ARK Investment Management LLC. It holds Chemomab Therapeutics’s shares valued at N/A.
---
Chemomab Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (349.59% Upside)
$8.00 (349.59% Upside)
Hedge Fund Trend
Decreased
By 792.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 29.7%
Last 30 Days ▲ 29.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
261.22%
12-Months-Change
Fundamentals
Return on Equity
-84.26%
Trailing 12-Months
Asset Growth
-10.76%
Trailing 12-Months
Company Description
Chemomab Therapeutics
Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.
---
CMMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(349.59% Upside)
Technical Analysis
Best Analysts Covering CMMB
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
-14.31%
reiterated a buy rating 27 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -14.31% per trade.
---